Herpes Simplex Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Sept. 15, 2011 - PRLog -- The global herpes simplex therapeutics market was worth approximately $2,350.1m in 2010. In 2005 the
market was valued at $2,513.8m and declined at a compound annual growth rate (CAGR) of 1.3% from
2005 to 2010. The global herpes simplex therapeutics market is expected to reach $3,947.4m by 2018, after growing at a CAGR of 6.7% from 2010. The primary factor contributing to the increase in revenues
over the forecast period is the expected launch of pipeline products. Presently, the therapeutic regimen
for herpes simplex is dominated by a range of DNA polymerase inhibitors, which include Zovirax (200mg
and 400mg), Famvir, Valtrex, Denavir and OTC (Over-the-Counter) products such as Abreva. Of these approved therapies Zovirax, Famvir and Valtrex have gone off patent. Topical therapies such as Abreva
and Denavir will lose their patents in 2014 and 2015, respectively. The herpes simplex therapeutics market is a significantly genericized market, with many brands across the seven geographies (the US, France, Germany, Italy, Spain, the UK and Japan). The herpes simplex pipeline is dominated by first in
class molecules. In the late stages of the pipeline, NB-001 is a novel topical treatment for oral herpes. It is being developed by NanoBio and is expected to launch in 2014. BA-021 another molecule in Phase III is being developed by BioAlliance in partnership with GlaxoSmithKline (GSK). BA021 is expected to launch in the market in 2013. In addition to these drugs, the pipeline consists of many novel therapies that will drive market growth in the future. This is dependent on whether they are able to produce satisfactory results and pass through the regulatory hurdles.

GlobalData’s pipeline analysis revealed that there are 27 candidates in the various stages of clinical development. There are 20 first in class molecules across all the phases of development. The Phase III
stage of development consists of two molecules. These are NB-001 and BA021. Of these, NB-001 is first
in class, whereas BA021 is a product extension. Phase II has six pipeline molecules. There are five molecules in Phase I. The preclinical and discovery stage combined consist of fourteen molecules. NB- 001, BA021, AIC316 and RPI-78M are among the promising drugs under clinical development. NB-001 is
a novel drug under Phase III development by NanoBio in partnership with GSK. In Phase II trial results,
NB-001 has shown significant antimicrobial activity against the HSV that causes herpes labialis. BA021 (acyclovir lauriad) is being developed by BioAlliance and is based on mucoadhesive oral tablet technology. AIC316 is being developed by AiCuris. The company has completed Phase II trials two months earlier than the expected trial completion time and is seeking partners for the further development of the drug. RPI-78M is a novel antiviral drug being developed by Nutra Pharma Corporation. NB-001 and BA021 are expected to be launched in the market during the late forecast period and will contribute to the growth in the market.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

The herpes simplex therapeutics market has significant unmet need. The currently marketed antivirals are efficacious in treating herpes simplex symptomatically by healing the lesion faster. However, significant unmet need lies in the therapeutic market as the approved antivirals in the market are only able to reduce the frequency of herpes simplex reoccurrence to a certain extent. These drugs also require frequent dosing, which leads to a reduction in patient compliance. A significant unmet need also lies within the prophylactic market of herpes simplex.
GlobalData, the industry analysis specialist, has released its new report, “Herpes Simplex Therapeutics
– Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information
and analysis on the global alopecia market. The report identifies the key trends shaping and driving the
global alopecia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global alopecia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Herp...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.